Originally published Dec. 12. SAN ANTONIO, TEX. – Fifteen years after it came on the market, Herceptin is still the poster child for personalized medicine, and when combined with chemotherapy it's still the standard of care for HER2-positive breast cancer.
Having validated the performance of its mass spec-based TIQUAS system for the identification of protein biomarkers in clinical samples, proteomics firm Activiomics is now aiming to step up its biomarker development efforts.
Regulus Therapeutics this week announced that it has selected its first drug candidate, RG-101 for the treatment of hepatitis C. However, the company said it will develop the compound on its own despite an ongoing collaboration on the disease with GlaxoSmithKline.